Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer

T-cell therapies, such as chimeric antigen receptor (CAR) T-cell, bispecific T-cell engager (BiTE) and tumor-infiltrating lymphocyte (TIL) therapies, fight cancer cells harboring specific tumor antigens. However, activation of the immune response by these therapies can lead to a systemic inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganatra, Sarju, Dani, Sourbha S., Yang, Eric H., Zaha, Vlad G., Nohria, Anju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Primers in Cardio-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830211/
https://www.ncbi.nlm.nih.gov/pubmed/36636447
http://dx.doi.org/10.1016/j.jaccao.2022.07.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830211/
https://www.ncbi.nlm.nih.gov/pubmed/36636447
http://dx.doi.org/10.1016/j.jaccao.2022.07.014

Ejemplares similares